Answers are grounded in this paper and cite their sources.
Background: COVID-19, or coronavirus disease, was declared a pandemic by the WHO in 2020. Coronavirus 2 (SARS-CoV-2) is the infectious agent responsible for this disease. The antibodies that the human body makes in reaction to a viral infection include IgM and IgG. The body will display different clinical indications according on how effectively it generates antibodies. Investigate the relationship between COVID-19 patients' clinical manifestations and their levels of IgG Anti-SARS-Cov-2 antibodies in Bengkulu City in 2020. The severity of clinical signs and symptoms during the sickness influences the level of antibody response generated. Methods: Descriptive research methodologies are utilized in this study, which is a retrospective. The sample strategy employed was consecutive sampling with non-probability sampling. The level of clinical manifestation of COVID-19 patients is established by the Indonesian Ministry of Health using its 2021 categorization. When looking for a connection between the two variables, the Pearson correlation test was used. Results: The research methods used in this study are descriptive and are structured like a retrospective. A non-probability sampling strategy based on the progressive sampling method was used to collect the samples. The Indonesian Ministry of Health will categorize COVID-19 patients in 2021 based on their clinical manifestation level. To look at the link between the two variables, we used the Pearson correlation test. Conclusion: Levels of IgG anti-SARS-Cov-2 antibodies and clinical symptoms in COVID-19 patients who have recovered in Bengkulu City are linked.
No takes yet. Share an insight, caveat, or question.
Nugraheni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: